doi: 10.1210/endo.139.4.5921 48 NauckMABartelsEOrskovCEbertRCreutzfeldtW
On women who thought they'd have to quit their GLP-1
Note that these outcomes were achieved in combination with diet and exercise, underlining the value of a holistic approach to weight loss and blood sugar management
A new systematic review published in the journal eClinicalMedicine on Wednesday examined 48 studies that analyzed and predicted the outcomes of people who either had diabetes or were overweight or obese and took popular GLP-1 medications such as liraglutide (under brand names such as Victoza and Saxenda), semaglutide (under brand names such as Ozempic, Wegovy, Rybelsus) and tirzepatide (under brand names like Mounjaro and Zepbound)
Support & Care Breakdown Live Chat Human In-app chat support is available 24/7, staffed by real people who are polite and responsive
Real-world adherence: weekly injections (semaglutide) or daily oral tablets (resmetirom) appear manageable, but longitudinal adherence in asymptomatic patients may falter
